» Articles » PMID: 27832378

Cell Entry of C3 Exoenzyme from Clostridium Botulinum

Overview
Date 2016 Nov 11
PMID 27832378
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Clostridium botulinum C3 is the prototype of C3-like ADP-ribosyltransferases that selectively ADP-ribosylate the small GTP-binding proteins RhoA/B/C and inhibit their downstream signaling pathways. It is used as pharmacological tool to study cellular Rho functions. In addition, C3bot harbors a transferase-independent activity on neurons to promote axonal and dendritic growth and branching. Many bacterial protein toxins interact specifically with proteins and/or other membrane components at the surface of target cells. Binding enables access to the appropriate cellular compartment so that the knowledge of the receptor allows essential insight into the mechanism of these toxins. Unlike other bacterial protein toxins (such as the clostridial C1 and C2 toxins from C. botulinum), C3 exoenzyme is devoid of a binding and translocation domain, with which toxins usually initiate receptor-mediated endocytosis followed by access to the intact cell. To date, no specific mechanism for internalization of C3 exoenzyme has been identified. Recently, vimentin was identified as membranous C3-binding partner involved in binding and uptake of C3. Although vimentin is not detected in neurons, vimentin is re-expressed after damage in regenerating neurons. Reappearance of vimentin allows C3 to get access to lesioned neurons/axons to exhibit axonotrophic and dentritotrophic effects.

Citing Articles

Microbiome-Stealth Regulator of Breast Homeostasis and Cancer Metastasis.

Furuta S Cancers (Basel). 2024; 16(17).

PMID: 39272898 PMC: 11394247. DOI: 10.3390/cancers16173040.


Effects of the Rho/Rho-Kinase Pathway on Perfusion Pressure in the Isolated-Perfused Rat Hind Limb Vascular Bed.

Ilhan E, Buyukafsar K, Tiftik R, Secilmis M, Alzayed Z Balkan Med J. 2021; 38(5):304-309.

PMID: 34558416 PMC: 8880892. DOI: 10.5152/balkanmedj.2021.20014.


Several New Putative Bacterial ADP-Ribosyltransferase Toxins Are Revealed from In Silico Data Mining, Including the Novel Toxin Vorin, Encoded by the Fire Blight Pathogen .

Tremblay O, Thow Z, Merrill A Toxins (Basel). 2020; 12(12).

PMID: 33322547 PMC: 7764402. DOI: 10.3390/toxins12120792.


An In-Silico Sequence-Structure-Function Analysis of the N-Terminal Lobe in CT Group Bacterial ADP-Ribosyltransferase Toxins.

Lugo M, Merrill A Toxins (Basel). 2019; 11(6).

PMID: 31234283 PMC: 6628389. DOI: 10.3390/toxins11060365.


Inhibition of RhoA reduces propofol-mediated growth cone collapse, axonal transport impairment, loss of synaptic connectivity, and behavioural deficits.

Pearn M, Schilling J, Jian M, Egawa J, Wu C, Mandyam C Br J Anaesth. 2018; 120(4):745-760.

PMID: 29576115 PMC: 6200100. DOI: 10.1016/j.bja.2017.12.033.

References
1.
Wahl S, Barth H, Ciossek T, Aktories K, Mueller B . Ephrin-A5 induces collapse of growth cones by activating Rho and Rho kinase. J Cell Biol. 2000; 149(2):263-70. PMC: 2175154. DOI: 10.1083/jcb.149.2.263. View

2.
Wang Z, Pandey A, Hart G . Dynamic interplay between O-linked N-acetylglucosaminylation and glycogen synthase kinase-3-dependent phosphorylation. Mol Cell Proteomics. 2007; 6(8):1365-79. DOI: 10.1074/mcp.M600453-MCP200. View

3.
Boquet P, Munro P, Fiorentini C, Just I . Toxins from anaerobic bacteria: specificity and molecular mechanisms of action. Curr Opin Microbiol. 1999; 1(1):66-74. DOI: 10.1016/s1369-5274(98)80144-6. View

4.
Chardin P, Boquet P, Madaule P, Popoff M, Rubin E, Gill D . The mammalian G protein rhoC is ADP-ribosylated by Clostridium botulinum exoenzyme C3 and affects actin microfilaments in Vero cells. EMBO J. 1989; 8(4):1087-92. PMC: 400918. DOI: 10.1002/j.1460-2075.1989.tb03477.x. View

5.
Barth H, Hofmann F, Olenik C, Just I, Aktories K . The N-terminal part of the enzyme component (C2I) of the binary Clostridium botulinum C2 toxin interacts with the binding component C2II and functions as a carrier system for a Rho ADP-ribosylating C3-like fusion toxin. Infect Immun. 1998; 66(4):1364-9. PMC: 108061. DOI: 10.1128/IAI.66.4.1364-1369.1998. View